145 related articles for article (PubMed ID: 37545011)
1. Repeated infusions of ketamine for treatment-resistant bipolar depression in real-world practice.
Zhou Y; Chen X; Ning Y
Bipolar Disord; 2023 Sep; 25(6):515-516. PubMed ID: 37545011
[No Abstract] [Full Text] [Related]
2. Progress in treatment-resistant bipolar depression using repeated ketamine infusions.
van den Brink W; van Amsterdam J
Bipolar Disord; 2023 Sep; 25(6):517-518. PubMed ID: 37311591
[No Abstract] [Full Text] [Related]
3. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
[TBL] [Abstract][Full Text] [Related]
4. Ketamine as an alternative treatment for treatment-resistant depression.
Dowben JS; Grant JS; Keltner NL
Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
[No Abstract] [Full Text] [Related]
5. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
[TBL] [Abstract][Full Text] [Related]
6. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH
Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic.
Rosenblat JD; Lipsitz O; Di Vincenzo JD; Rodrigues NB; Kratiuk K; Subramaniapillai M; Lee Y; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Wong L; Mansur RB; McIntyre RS
Psychiatry Res; 2021 Sep; 303():114086. PubMed ID: 34246008
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
10. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
12. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Subramaniapillai M; Kratiuk K; Majeed A; Nasri F; Gill H; Mansur RB; Rosenblat JD
Psychiatry Res; 2021 Jun; 300():113860. PubMed ID: 33836470
[TBL] [Abstract][Full Text] [Related]
13. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
14. Ketamine for Treatment-Resistant bipolar depression-A reality check!
Singh B
Bipolar Disord; 2023 May; 25(3):247-248. PubMed ID: 36978284
[No Abstract] [Full Text] [Related]
15. Ketamine for treatment-resistant bipolar depression-need for more data!
Singh B; Vande Voort JL; Kung S
Bipolar Disord; 2021 Nov; 23(7):728-729. PubMed ID: 34549861
[No Abstract] [Full Text] [Related]
16. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
[TBL] [Abstract][Full Text] [Related]
17. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE).
McIntyre RS; Rosenblat JD; Rodrigues NB; Lipsitz O; Chen-Li D; Lee JG; Nasri F; Subramaniapillai M; Kratiuk K; Wang A; Gill H; Mansur RB; Ho R; Lin K; Lee Y
Psychiatry Res; 2021 Aug; 302():113993. PubMed ID: 34034067
[TBL] [Abstract][Full Text] [Related]
18. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
[TBL] [Abstract][Full Text] [Related]
20. National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
Niciu MJ; Meisner RC; Carr BR; Farooqui AA; Feifel D; Kaplin A; Kendrick EJ; Kim PM; Schneck CD; Vande Voort JL; Parikh SV
J Affect Disord; 2024 Feb; 346():221-222. PubMed ID: 37940059
[No Abstract] [Full Text] [Related]
[Next] [New Search]
